Age-Dependent Effect of &bgr;-Blockers in Preventing Vasovagal Syncope

Background—&bgr;-blockers have little effectiveness in preventing vasovagal syncope in unselected populations, but they might be effective in older patients. We determined whether &bgr;-blockers prevent vasovagal syncope in an age-related fashion. Methods and Results—Two populations were studied. A proportional hazards analysis was performed on an observational cohort study of 153 patients with vasovagal syncope, 52 of whom received &bgr;-blockers. A multivariable proportional hazards model stratified by center was performed on 208 participants in the randomized Prevention of Syncope Trial (POST), examining the interaction between age group and treatment with metoprolol. Age-specific hazard ratios were estimated for both studies and combined using the inverse variance meta-analytic method. In the cohort study, the hazard ratio for syncope if treated with &bgr;-blockers was 1.54 (95% CI, 0.78–3.05) for patients aged <42 years and 0.48 (95% CI, 0.12–1.92) for patients aged ≥42 years. In POST, the proportional hazards model showed interactions between age and treatment effect (P=0.026). The hazard ratio for patients aged ≥42 years who received metoprolol was 0.53 (95% CI, 0.25–1.10); in patients aged <42 years, the hazard ratio was 1.62 (95% CI, 0.85–3.10). A pooled analysis of both studies yielded an estimate of the hazard ratio of 1.58 (CI, 1.00–2.31) for patients aged <42 years, and the hazard ratio was 0.52 (CI, 0.27–1.01) for patients aged ≥42 years. The 2 age groups differed significantly in response to &bgr;-blockers (P=0.007). Conclusions—&bgr;-blocker treatment may suppress vasovagal syncope in middle-aged patients aged >42 years.

[1]  J. Blanc,et al.  Pacemaker Therapy in Patients With Neurally Mediated Syncope and Documented Asystole: Third International Study on Syncope of Uncertain Etiology (ISSUE-3) A Randomized Trial , 2012, Circulation.

[2]  S. Raj,et al.  Rationale for the prevention of syncope trial IV: assessment of midodrine , 2012, Clinical Autonomic Research.

[3]  Sally Hopewell,et al.  Erratum to: “CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials” [J Clin Epidemiol 2010;63(8):e1–37] , 2012 .

[4]  Eloise E Kaizar.  Estimating treatment effect via simple cross design synthesis , 2011, Statistics in medicine.

[5]  Su Golder,et al.  Meta-analyses of Adverse Effects Data Derived from Randomised Controlled Trials as Compared to Observational Studies: Methodological Overview , 2011, PLoS medicine.

[6]  M. Brignole,et al.  The Diagnosis and Management of Syncope , 2010, Current hypertension reports.

[7]  S. Iliceto,et al.  Age-related hemodynamic changes during vasovagal syncope , 2010, Autonomic Neuroscience.

[8]  Matthias Egger,et al.  CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials , 2010, BMJ : British Medical Journal.

[9]  J. Blanc,et al.  Guidelines for the diagnosis and management of syncope (version 2009) The Task Force for the Diagnosis and Management of Syncope of the European Society of Cardiology (ESC) , 2009 .

[10]  M. Cheung,et al.  Bisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomized controlled trials and observational studies , 2009, BMC musculoskeletal disorders.

[11]  Cheng Wang,et al.  [Efficacy of midodrine hydrochloride in the treatment of children with vasovagal syncope]. , 2009, Zhonghua yi xue za zhi.

[12]  B. Westerhof,et al.  Steep fall in cardiac output is main determinant of hypotension during drug-free and nitroglycerine-induced orthostatic vasovagal syncope. , 2008, Heart rhythm.

[13]  R. Sheldon,et al.  Evidence-based treatment for vasovagal syncope. , 2008, Heart rhythm.

[14]  R. Kunz.  Randomized trials and observational studies: still mostly similar results, still crucial differences. , 2008, Journal of clinical epidemiology.

[15]  S. Raj,et al.  The Second Prevention of Syncope Trial (POST II)--a randomized clinical trial of fludrocortisone for the prevention of neurally mediated syncope: rationale and study design. , 2006, American heart journal.

[16]  S. Connolly,et al.  Prevention of Syncope Trial (POST): A Randomized, Placebo-Controlled Study of Metoprolol in the Prevention of Vasovagal Syncope , 2006, Circulation.

[17]  S. Connolly,et al.  Diagnostic criteria for vasovagal syncope based on a quantitative history. , 2006, European heart journal.

[18]  S. Connolly,et al.  Age of First Faint in Patients with Vasovagal Syncope , 2006, Journal of cardiovascular electrophysiology.

[19]  K. Lurie,et al.  Comparison of catecholamine response during tilt-table-induced vasovagal syncope in patients 65 years of age. , 2004 .

[20]  B. Gersh,et al.  Comparison of frequency of recurrent syncope after beta-blocker therapy versus conservative management for patients with vasovagal syncope. , 2003, The American journal of cardiology.

[21]  H. Kaufmann,et al.  Midodrine in neurally mediated syncope: A double‐blind, randomized, crossover study , 2002, Annals of neurology.

[22]  G. Leftheriotis,et al.  Comparison between isoproterenol and nitroglycerin sensitized head-upright tilt in patients with unexplained syncope and negative or positive passive head-up tilt response. , 2002, The American journal of cardiology.

[23]  D. Kremastinos,et al.  Vasovagal syncope: a prospective, randomized, crossover evaluation of the effect of propranolol, nadolol and placebo on syncope recurrence and patients' well-being. , 2002, Journal of the American College of Cardiology.

[24]  D. Goldstein,et al.  Meta-analysis of nonselective versus beta-1 adrenoceptor-selective blockade in prevention of tilt-induced neurocardiogenic syncope. , 2002, The American journal of cardiology.

[25]  T. Meinertz,et al.  A Randomized and Controlled Pilot Trial of β‐blockers for the Treatment of Recurrent Syncope in Patients with a Positive or Negative Response to Head‐Up Tilt Test , 2002, Pacing and clinical electrophysiology : PACE.

[26]  J. Segovia,et al.  Lack of efficacy of atenolol for the prevention of neurally mediated syncope in a highly symptomatic population: a prospective, double-blind, randomized and placebo-controlled study. , 2001, Journal of the American College of Cardiology.

[27]  D. Kremastinos,et al.  Provocation of neurocardiogenic syncope by clomipramine administration during the head-up tilt test in vasovagal syndrome. , 2000, Journal of the American College of Cardiology.

[28]  E. Werstiuk,et al.  Vascular β-adrenoceptor function in hypertension and in ageing , 2000 .

[29]  R. Sheldon,et al.  Usefulness of clinical factors in predicting outcomes of passive tilt tests in patients with syncope. , 2000, The American journal of cardiology.

[30]  R. Kenny,et al.  Midodrine: a role in the management of neurocardiogenic syncope , 1998, Heart.

[31]  R. Sheldon,et al.  Comparison of patients with syncope of unknown cause having negative or positive tilt-table tests. , 1997, The American journal of cardiology.

[32]  A. Natale,et al.  Response to Beta Blockers in Patients with Neurocardiogenic Syncope: How to Predict Beneficial Effects , 1996, Journal of cardiovascular electrophysiology.

[33]  R. Horton.  CONSORT , 1996, The Lancet.

[34]  P. Flanagan,et al.  Effect of beta blockers on the time to first syncope recurrence in patients after a positive isoproterenol tilt table test. , 1996, The American journal of cardiology.

[35]  A. Castellanos,et al.  Acute and long-term beta-adrenergic blockade for patients with neurocardiogenic syncope. , 1996, Journal of the American College of Cardiology.

[36]  P. Flanagan,et al.  Risk factors for syncope recurrence after a positive tilt-table test in patients with syncope. , 1996, Circulation.

[37]  K. Nademanee,et al.  Randomized double-blind, placebo-controlled trial of oral atenolol in patients with unexplained syncope and positive upright tilt table test results. , 1995, American heart journal.

[38]  J. Marín.  Age-related changes in vascular responses: a review , 1995, Mechanisms of Ageing and Development.

[39]  R. Sheldon.  Effects of aging on responses to isoproterenol tilt-table testing in patients with syncope. , 1994, The American journal of cardiology.

[40]  P. Grambsch,et al.  Proportional hazards tests and diagnostics based on weighted residuals , 1994 .

[41]  A. Shoukas,et al.  Alpha- and beta-adrenergic mechanisms in the control of vascular capacitance by the carotid sinus baroreflex system. , 1994, The American journal of physiology.

[42]  J. Leor,et al.  Absence of tachycardia during tilt test predicts failure of beta-blocker therapy in patients with neurocardiogenic syncope. , 1994, American heart journal.

[43]  R. Sheldon,et al.  Methodology of isoproterenol-tilt table testing in patients with syncope. , 1992, Journal of the American College of Cardiology.

[44]  C. Gornick,et al.  Provocation of bradycardia and hypotension by isoproterenol and upright posture in patients with unexplained syncope. , 1989, The New England journal of medicine.

[45]  Ian Shrier,et al.  Should meta-analyses of interventions include observational studies in addition to randomized controlled trials? A critical examination of underlying principles. , 2007, American journal of epidemiology.

[46]  K. Lurie,et al.  Comparison of catecholamine response during tilt-table-induced vasovagal syncope in patients <35 to those >65 years of age. , 2004, The American journal of cardiology.

[47]  S. Connolly,et al.  Prevention of Syncope Trial (POST): a randomized clinical trial of beta blockers in the prevention of vasovagal syncope; rationale and study design. , 2003, Europace.

[48]  E. Werstiuk,et al.  Vascular beta-adrenoceptor function in hypertension and in ageing. , 2000, Canadian journal of physiology and pharmacology.

[49]  T Länne,et al.  Cardiovascular response to acute hypovolemia in relation to age. Implications for orthostasis and hemorrhage. , 2000, American journal of physiology. Heart and circulatory physiology.

[50]  Ken W. Woodhouse,et al.  The Clinical Perspective , 1994 .